What changed
Eli Lilly's GLP-1 franchise is projected to drive $137 billion in global sales by 2032, anchored by its weight-loss drugs, while Viking Therapeutics' VK2735 (a dual GLP-1/GIP receptor agonist) is generating positive sentiment that lifts the entire class. Merck reported positive Phase 3 results for tulisokibart in ulcerative colitis, and Amgen continues to develop its own obesity pipeline, broadening the competitive landscape. The GLP-1 and metabolic disease space is becoming a multi-company structural growth theme that extends well beyond Novo Nordisk and Lilly.
How this relates
Recent coverage adds a new development to this thesis — surfaced by cross-referencing fresh news against the existing catalog.
Articles rss:ylrsae (Lilly's $137B 2032 sales forecast driven by weight-loss drugs), rss:plnne6 (Viking's VK2735 rally lifting GLP-1 sentiment broadly), and rss:1cey2dc (Merck Phase 3 positive results) collectively point to a broadening GLP-1 and metabolic disease pipeline theme. The existing 'concept-healthcare-rotation-ai-selloff-hedge' thesis covers LLY, NVO, AMGN, ABBV, MRK as defensive rotation names, but does not articulate the GLP-1 pipeline expansion as a standalone structural growth thesis. The existing 'concept-abbvie-largecap-pharma-ma-pipeline-build' thesis covers M&A pipeline building. This is a distinct, new angle: the GLP-1 drug class itself as a multi-year revenue driver across multiple companies.
Sources
- Thinking Thin Pays Off: Lilly To Dominate Pharma World By 2032
- VKTX Stock Clocks Best Day In Nearly 3 Months On Obesity Pipeline Optimism, Buyout Speculation
- How New Immunology and Vaccine Milestones At Merck (MRK) Have Changed Its Investment Story
- Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Cross-referenced from concept generation (evolves → concept-healthcare-rotation-ai-selloff-hedge). Research notes, not financial advice.